Cdk5 Inhibitors
Cdk5 Inhibitors - Related Videos
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
02:08
Assessing Bacterial Swarming Using a Gradient Inhibitor Plate
0 Views •
2025
Source: Guo, S., et al. Quantifying Bacterial Surface Swarming Motility on Inducer Gradient Plates. J. Vis. Exp. (2022).This video demonstrates the use of a double-layer gradient swarm plate to study bacterial swarming behavior under varying inhibitor concentrations. A plate with a gradient-forming inhibitor in the bottom layer is inoculated with bacteria and incubated. Images are captured at regular intervals to analyze the effect of inhibitor concentration on bacterial swarming.
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
0 Views •
Cited by 4 •
2015
We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.
02:57
Evaluating Inhibitor Effects on Pellicle Formation in Bacillus subtilis
0 Views •
2026
Source: Bucher, T., et al. Methodologies for Studying B. subtilis Biofilms as a Model for Characterizing Small Molecule Biofilm Inhibitors. J. Vis. Exp. (2016)This video demonstrates a pellicle formation assay using Bacillus subtilis to evaluate small-molecule inhibitors that disrupt matrix synthesis and biofilm development, providing a model to screen compounds that selectively inhibit surface-associated growth without affecting free-floating cells.
FAQs
They can suppress Cdk5 in at least two conceptually distinct ways: directly interfering with its catalytic activity or disrupting activation by regulatory proteins such as p35 and p39. This distinction matters because both strategies reduce phosphorylation of downstream neuronal substrates, but they target different points in the signaling process and can help researchers interpret pathway-specific effects.
p35 and p39 regulate Cdk5 activation, so inhibitors that interfere with these interactions address a different control point than compounds acting on the catalytic site. Examining both mechanisms helps distinguish whether reduced downstream phosphorylation results from blocking enzyme activity itself or from preventing formation or function of an activated regulatory complex.
Abnormal Cdk5 signaling has been linked in the provided context to synaptic dysfunction, cytoskeletal changes, and neuronal injury. These outcomes connect kinase regulation with several levels of neuronal pathology, allowing inhibitor studies to examine whether limiting Cdk5-dependent phosphorylation changes cellular processes associated with neurodegenerative disease mechanisms.
In neuroscience research, these compounds serve as experimental tools for reducing Cdk5 signaling and then examining associated neuronal effects. Comparing inhibited and uninhibited conditions can help clarify how Cdk5 contributes to synaptic function, cytoskeletal organization, or neuronal injury, while also testing whether the kinase is a meaningful target in disease-related mechanisms.
Studies can assess whether limiting Cdk5 activity is associated with changes in phosphorylation of downstream neuronal substrates and with alterations related to synaptic dysfunction, cytoskeletal changes, or neuronal injury. Together, these outcomes provide mechanistic evidence connecting kinase signaling to neuronal behavior and help identify which consequences are most closely associated with abnormal pathway activity.
Selectivity and toxicity are central barriers to translating experimental Cdk5 inhibitors into clinical applications. A compound may reduce the intended kinase pathway yet still present safety concerns or insufficiently specific effects. Consequently, inhibitor research supports therapeutic-target evaluation, but evidence of pathway modulation alone does not establish that a candidate is suitable for clinical use.